A a prospective, open-label, non-randomized single-centre study to evaluate riociguat in patients with pulmonary hypertension due to heart failure with preserved ejection fraction

Trial Profile

A a prospective, open-label, non-randomized single-centre study to evaluate riociguat in patients with pulmonary hypertension due to heart failure with preserved ejection fraction

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary hypertension
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 27 Oct 2015 New trial record
    • 29 Aug 2015 Results published at ESC Congress 2015: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top